FLT3 and acute myeloid leukemia: It has been shown that for AML patients to achieve maximum clinical benefit, it is imperative that midostaurin be administered in combination with other anticancer agents.6, 8 Here, we investigate the effects of midostaurin alone against AML characterized as expressing either wt or mutant FLT3, as well as in combination with standard chemotherapy and targeted inhibitors.